Real-world data concerning the efficacy of molnupiravir in patients vaccinated against COVID-19 during the Omicron surge in Japan

DOI record: { "DOI": "10.21203/rs.3.rs-2451986/v1", "URL": "http://dx.doi.org/10.21203/rs.3.rs-2451986/v1", "abstract": "<jats:title>Abstract</jats:title>\n <jats:p>Molnupiravir is among the antiviral agents used to treat COVID-19; however, reported data on the efficacy of this drug are based on results from unvaccinated patients. As such, the efficacy of molnupiravir among vaccinated patients during the B1.1.529 (Omicron) variant outbreak remains unknown. To address this issue, this study retrospectively analyzed data from 294 vaccinated patients with COVID-19 who had at least one risk factor, between May and October 2022. Patients were divided into the molnupiravir group and the control group to investigate the correlations of molnupiravir and other factors with rates of hospitalization and death (hospitalization/death) within 28 days of admission. Potential risk factors were also examined. The study findings indicated that molnupiravir was not associated with the rate of hospitalization/death, while age ≥ 80 years, residence in a long-term care facility, and presence of chronic obstructive pulmonary disease were significantly associated with the rate of hospitalization/death. Although the current results suggest that the effect of vaccination in preventing severe illness against the Omicron variant is well maintained, additional studies on risk factors and outcomes are required to validate this study’s findings.</jats:p>", "accepted": { "date-parts": [ [ 2023, 1, 7 ] ] }, "author": [ { "affiliation": [ { "name": "Fukuchiyama City Hospital" } ], "family": "Inaba", "given": "Satoshi", "sequence": "first" }, { "affiliation": [ { "name": "Fukuchiyama City Hospital" } ], "family": "Nishioka", "given": "Naoya", "sequence": "additional" }, { "affiliation": [ { "name": "Fukuchiyama City Hospital" } ], "family": "Okumura", "given": "Hisatoshi", "sequence": "additional" }, { "affiliation": [ { "name": "Fukuchiyama City Hospital" } ], "family": "Nakao", "given": "Koshi", "sequence": "additional" }, { "affiliation": [ { "name": "Fukuchiyama City Hospital" } ], "family": "Hattori", "given": "Yu", "sequence": "additional" }, { "affiliation": [ { "name": "Fukuchiyama City Hospital" } ], "family": "Futamura", "given": "Shun", "sequence": "additional" }, { "affiliation": [ { "name": "Fukuchiyama City Hospital" } ], "family": "Hattori", "given": "Tomohito", "sequence": "additional" }, { "affiliation": [ { "name": "Fukuchiyama City Hospital" } ], "family": "Okabe", "given": "Kengo", "sequence": "additional" }, { "affiliation": [ { "name": "Fukuchiyama City Hospital" } ], "family": "Nishiyama", "given": "Daichi", "sequence": "additional" } ], "container-title": [], "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2023, 1, 16 ] ], "date-time": "2023-01-16T14:36:12Z", "timestamp": 1673879772000 }, "deposited": { "date-parts": [ [ 2023, 4, 4 ] ], "date-time": "2023-04-04T12:16:10Z", "timestamp": 1680610570000 }, "group-title": "In Review", "indexed": { "date-parts": [ [ 2023, 4, 5 ] ], "date-time": "2023-04-05T04:43:20Z", "timestamp": 1680669800369 }, "institution": [ { "name": "Research Square" } ], "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2023, 1, 16 ] ] }, "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0/", "content-version": "unspecified", "delay-in-days": 0, "start": { "date-parts": [ [ 2023, 1, 16 ] ], "date-time": "2023-01-16T00:00:00Z", "timestamp": 1673827200000 } } ], "link": [ { "URL": "https://www.researchsquare.com/article/rs-2451986/v1", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.researchsquare.com/article/rs-2451986/v1.html", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "8761", "original-title": [], "posted": { "date-parts": [ [ 2023, 1, 16 ] ] }, "prefix": "10.21203", "published": { "date-parts": [ [ 2023, 1, 16 ] ] }, "publisher": "Research Square Platform LLC", "reference": [ { "DOI": "10.1016/S0140-6736(22)00462-7", "article-title": "Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: A cohort study", "author": "Nyberg T", "doi-asserted-by": "crossref", "first-page": "1303", "journal-title": "Lancet", "key": "ref1", "unstructured": "Nyberg, T. et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: A cohort study. Lancet 399, 1303–1312 (2022).", "volume": "399", "year": "2022" }, { "DOI": "10.15585/mmwr.mm7104e3", "article-title": "Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and omicron variant predominance - VISION network, 10 states, August 2021–January 2022", "author": "Thompson MG", "doi-asserted-by": "crossref", "first-page": "139", "journal-title": "MMWR Morb. Mortal. Wkly Rep.", "key": "ref2", "unstructured": "Thompson, M. G. et al. Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and omicron variant predominance - VISION network, 10 states, August 2021–January 2022. MMWR Morb. Mortal. Wkly Rep. 71, 139–145 (2022).", "volume": "71", "year": "2022" }, { "article-title": "Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses", "author": "Yoon JJ", "first-page": "62", "journal-title": "Antimicrob. Agents Chemother.", "key": "ref3", "unstructured": "Yoon, J. J. et al. Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses. Antimicrob. Agents Chemother. 62 (2018).", "year": "2018" }, { "DOI": "10.1038/s41564-020-00835-2", "article-title": "Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets", "author": "Cox RM", "doi-asserted-by": "crossref", "first-page": "11", "journal-title": "Nat. Microbiol.", "key": "ref4", "unstructured": "Cox, R. M., Wolf, J. D. & Plemper, R. K. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat. Microbiol. 6, 11–18 (2021).", "volume": "6", "year": "2021" }, { "DOI": "10.1126/scitranslmed.abb5883", "article-title": "An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice", "author": "Sheahan TP", "doi-asserted-by": "crossref", "journal-title": "Sci. Transl. Med.", "key": "ref5", "unstructured": "Sheahan, T. P. et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 12 (2020).", "volume": "12", "year": "2020" }, { "DOI": "10.1038/s41586-021-03312-w", "article-title": "SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801", "author": "Wahl A", "doi-asserted-by": "crossref", "first-page": "451", "journal-title": "Nature", "key": "ref6", "unstructured": "Wahl, A. et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 591, 451–457 (2021).", "volume": "591", "year": "2021" }, { "DOI": "10.1093/infdis/jiab361", "article-title": "Molnupiravir inhibits replication of the emerging SARS-CoV-2 variants of concern in a hamster infection model", "author": "Abdelnabi R", "doi-asserted-by": "crossref", "first-page": "749", "journal-title": "J. Infect. Dis.", "key": "ref7", "unstructured": "Abdelnabi, R. et al. Molnupiravir inhibits replication of the emerging SARS-CoV-2 variants of concern in a hamster infection model. J. Infect. Dis. 224, 749–753 (2021).", "volume": "224", "year": "2021" }, { "article-title": "Small-molecule antiviral β-d-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance", "author": "Agostini ML", "first-page": "93", "journal-title": "J. Virol.", "key": "ref8", "unstructured": "Agostini, M. L. et al. Small-molecule antiviral β-d-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J. Virol. 93 (2019).", "year": "2019" }, { "DOI": "10.1056/NEJMoa2116044", "article-title": "Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients", "author": "Jayk Bernal A", "doi-asserted-by": "crossref", "first-page": "509", "journal-title": "N. Engl. J. Med.", "key": "ref9", "unstructured": "Jayk Bernal, A. et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N. Engl. J. Med. 386, 509–520 (2022).", "volume": "386", "year": "2022" }, { "DOI": "10.1056/NEJMoa2007764", "article-title": "Remdesivir for the treatment of Covid-19 - Final report", "author": "Beigel JH", "doi-asserted-by": "crossref", "first-page": "1813", "journal-title": "N. Engl. J. Med.", "key": "ref10", "unstructured": "Beigel, J. H. et al. Remdesivir for the treatment of Covid-19 - Final report. N. Engl. J. Med. 383, 1813–1826 (2020).", "volume": "383", "year": "2020" }, { "DOI": "10.1056/NEJMc2119407", "article-title": "Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant", "author": "Takashita E", "doi-asserted-by": "crossref", "first-page": "995", "journal-title": "N. Engl. J. Med.", "key": "ref11", "unstructured": "Takashita, E. et al. Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant. N. Engl. J. Med. 386, 995–998 (2022).", "volume": "386", "year": "2022" }, { "DOI": "10.1056/NEJMoa2118542", "article-title": "Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19", "author": "Hammond J", "doi-asserted-by": "crossref", "first-page": "1397", "journal-title": "N. Engl. J. Med.", "key": "ref12", "unstructured": "Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med. 386, 1397–1408 (2022).", "volume": "386", "year": "2022" }, { "DOI": "10.1038/bmt.2012.244", "article-title": "Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics", "author": "Kanda Y", "doi-asserted-by": "crossref", "first-page": "452", "journal-title": "Bone Marrow Transplant.", "key": "ref13", "unstructured": "Kanda, Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48, 452–458 (2013).", "volume": "48", "year": "2013" }, { "article-title": "Molnupiravir-A novel oral anti-SARS-CoV-2 agent", "author": "Lee CC", "first-page": "10", "journal-title": "Antibiotics (Basel)", "key": "ref14", "unstructured": "Lee, C. C., Hsieh, C. C. & Ko, W. C. Molnupiravir-A novel oral anti-SARS-CoV-2 agent. Antibiotics (Basel) 10 (2021).", "year": "2021" }, { "DOI": "10.1080/07853890.2022.2034936", "article-title": "Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis", "author": "Wen W", "doi-asserted-by": "crossref", "first-page": "516", "journal-title": "Ann. Med.", "key": "ref15", "unstructured": "Wen, W. et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. Ann. Med. 54, 516–523 (2022).", "volume": "54", "year": "2022" }, { "DOI": "10.1016/j.jsps.2022.03.002", "article-title": "The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review", "author": "Kamal L", "doi-asserted-by": "crossref", "first-page": "508", "journal-title": "Saudi Pharm. J.", "key": "ref16", "unstructured": "Kamal, L., Ramadan, A., Farraj, S., Bahig, L. & Ezzat, S. The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review. Saudi Pharm. J. 30, 508–518 (2022).", "volume": "30", "year": "2022" }, { "DOI": "10.1002/jmv.28011", "article-title": "Safety and efficacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience", "author": "Vito A", "doi-asserted-by": "crossref", "first-page": "5582", "journal-title": "J. Med. Virol.", "key": "ref17", "unstructured": "De Vito, A. et al. Safety and efficacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience. J. Med. Virol. 94, 5582–5588 (2022).", "volume": "94", "year": "2022" }, { "DOI": "10.3390/pathogens11101121", "article-title": "Molnupiravir as an early treatment for COVID-19: A real life study", "author": "Pontolillo M", "doi-asserted-by": "crossref", "journal-title": "Pathogens", "key": "ref18", "unstructured": "Pontolillo, M. et al. Molnupiravir as an early treatment for COVID-19: A real life study. Pathogens 11 (2022).", "volume": "11", "year": "2022" }, { "DOI": "10.1038/s41392-022-00997-x", "article-title": "SARS-CoV-2 Omicron variant: Recent progress and future perspectives", "author": "Fan Y", "doi-asserted-by": "crossref", "first-page": "141", "journal-title": "Signal Transduct. Target. Ther.", "key": "ref19", "unstructured": "Fan, Y. et al. SARS-CoV-2 Omicron variant: Recent progress and future perspectives. Signal Transduct. Target. Ther. 7, 141 (2022).", "volume": "7", "year": "2022" }, { "DOI": "10.1136/bmj.n3103", "article-title": "Covid-19: Runny nose, headache, and fatigue are commonest symptoms of omicron, early data show", "author": "Iacobucci G", "doi-asserted-by": "crossref", "first-page": "n3103", "journal-title": "BMJ", "key": "ref20", "unstructured": "Iacobucci, G. Covid-19: Runny nose, headache, and fatigue are commonest symptoms of omicron, early data show. BMJ 375, n3103 (2021).", "volume": "375", "year": "2021" }, { "article-title": "SARS-CoV-2 Omicron variant: Characteristics and prevention", "author": "He X", "first-page": "838", "journal-title": "Med.", "key": "ref21", "unstructured": "He, X., Hong, W., Pan, X., Lu, G. & Wei, X. SARS-CoV-2 Omicron variant: Characteristics and prevention. Med. 2, 838–845 (2021).", "volume": "2", "year": "2021" }, { "DOI": "10.1016/S0140-6736(22)00056-3", "article-title": "Omicron severity: Milder but not mild", "author": "Nealon J", "doi-asserted-by": "crossref", "first-page": "412", "journal-title": "Lancet", "key": "ref22", "unstructured": "Nealon, J. & Cowling, B. J. Omicron severity: Milder but not mild. Lancet 399, 412–413 (2022).", "volume": "399", "year": "2022" }, { "DOI": "10.1001/jama.2022.2274", "article-title": "Estimates of SARS-CoV-2 omicron variant severity in Ontario, Canada", "author": "Ulloa AC", "doi-asserted-by": "crossref", "first-page": "1286", "journal-title": "JAMA", "key": "ref23", "unstructured": "Ulloa, A. C., Buchan, S. A., Daneman, N. & Brown, K. A. Estimates of SARS-CoV-2 omicron variant severity in Ontario, Canada. JAMA 327, 1286–1288 (2022).", "volume": "327", "year": "2022" }, { "DOI": "10.1001/jama.2021.19499", "article-title": "Association between mRNA vaccination and COVID-19 hospitalization and disease severity", "author": "Tenforde MW", "doi-asserted-by": "crossref", "first-page": "2043", "journal-title": "JAMA", "key": "ref24", "unstructured": "Tenforde, M. W. et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA 326, 2043–2054 (2021).", "volume": "326", "year": "2021" }, { "DOI": "10.1056/NEJMoa2119451", "article-title": "Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant", "author": "Andrews N", "doi-asserted-by": "crossref", "first-page": "1532", "journal-title": "N. Engl. J. Med.", "key": "ref25", "unstructured": "Andrews, N. et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N. Engl. J. Med. 386, 1532–1546 (2022).", "volume": "386", "year": "2022" }, { "article-title": "Clinical severity and mRNA vaccine effectiveness for omicron, delta, and alpha SARS-CoV-2 variants in the United States: A prospective observational study", "author": "Lauring AS", "journal-title": "medRxiv", "key": "ref26", "unstructured": "Lauring, A. S. et al. Clinical severity and mRNA vaccine effectiveness for omicron, delta, and alpha SARS-CoV-2 variants in the United States: A prospective observational study. medRxiv (2022).", "year": "2022" }, { "article-title": "Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): An open-label, platform-adaptive randomised controlled trial", "author": "Butler CC", "journal-title": "Lancet", "key": "ref27", "unstructured": "Butler, C. C. et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): An open-label, platform-adaptive randomised controlled trial. Lancet (2022).", "year": "2022" }, { "DOI": "10.1016/S1473-3099(22)00507-2", "article-title": "Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA.2 wave: A retrospective cohort study", "author": "Wong CKH", "doi-asserted-by": "crossref", "first-page": "1681", "journal-title": "Lancet Infect. Dis.", "key": "ref28", "unstructured": "Wong, C. K. H. et al. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA.2 wave: A retrospective cohort study. Lancet Infect. Dis. 22, 1681–1693 (2022).", "volume": "22", "year": "2022" }, { "DOI": "10.1002/jmv.25889", "article-title": "The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis", "author": "Zhao Q", "doi-asserted-by": "crossref", "first-page": "1915", "journal-title": "J. Med. Virol.", "key": "ref29", "unstructured": "Zhao, Q. et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J. Med. Virol. 92, 1915–1921 (2020).", "volume": "92", "year": "2020" }, { "DOI": "10.1016/j.eclinm.2021.100789", "article-title": "COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis", "author": "Gerayeli FV", "doi-asserted-by": "crossref", "first-page": "100789", "journal-title": "EClinicalmedicine", "key": "ref30", "unstructured": "Gerayeli, F. V. et al. COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. EClinicalmedicine 33, 100789 (2021).", "volume": "33", "year": "2021" }, { "DOI": "10.1164/rccm.202108-1901OC", "article-title": "Increased SARS-CoV-2 infection, protease, and inflammatory responses in chronic obstructive pulmonary disease primary bronchial epithelial cells defined with single-cell RNA sequencing", "author": "Johansen MD", "doi-asserted-by": "crossref", "first-page": "712", "journal-title": "Am. J. Respir. Crit. Care Med.", "key": "ref31", "unstructured": "Johansen, M. D. et al. Increased SARS-CoV-2 infection, protease, and inflammatory responses in chronic obstructive pulmonary disease primary bronchial epithelial cells defined with single-cell RNA sequencing. Am. J. Respir. Crit. Care Med. 206, 712–729 (2022).", "volume": "206", "year": "2022" } ], "reference-count": 31, "references-count": 31, "relation": {}, "resource": { "primary": { "URL": "https://www.researchsquare.com/article/rs-2451986/v1" } }, "score": 1, "short-title": [], "source": "Crossref", "subtitle": [], "subtype": "preprint", "title": "Real-world data concerning the efficacy of molnupiravir in patients vaccinated against COVID-19 during the Omicron surge in Japan", "type": "posted-content" }